~~<i id='9D0838AF93'><strike id='9D0838AF93'><tt id='9D0838AF93'><pre id='9D0838AF93'></pre></tt></strike></i>~~

Home» knowledge» leisure time

leisure time

author：comprehensive 2025-09-06 08:37:28 Page View：41

A green number 3 with an eye is surrounded by smaller, black number 3s on a purple background — 3 to watch coverage from STAT — Christine Kao/STAT

Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.

The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.

Here are three CRISPR developments we’re watching in 2024:

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Was Amgen transparent enough on FDA's concern on cancer drug?
Next article： Heart attack and stroke risk calculators need revising

explore

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

DarronCummings/APAcouplebillionhere,acouplebillionthere,andprettysoonEliLillyhopesitwillbetalkingabo

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

STAT's guide to the next generation of CAR

MollyFergusonforSTATCAR-Tcelltherapyhasbeenaboonfortreatingbloodcancers.Sincethetechnologywasfirstbr